)
)
LIDDS Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from LIDDS
Access all reports
LIDDS AB is a Swedish pharmaceutical company that focuses on drug delivery technologies, particularly for cancer treatment. Its proprietary technology, NanoZolid, enables localized and controlled release of drugs for up to six months, reducing systemic side effects. LIDDS leverages this platform to develop its own oncology-focused pipeline, which includes candidates such as Nanodotax (a NanoZolid-formulated chemotherapy) and Nanoimod (a TLR9 agonist for cancer immunotherapy). The company's strategy also involves partnering with other pharmaceutical firms to enhance drug efficacy and safety using its drug delivery technology. LIDDS is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Texas Instruments: From Calculators to Master Capital Allocators
Texas Instruments has undergone many transformations from its origins in oil exploration to become one of the world's largest semiconductor producers.
11 Oct 2024
)
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
)
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Ticker symbol
LIDDS
Country
🇸🇪 Sweden